Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men

Richard Markus¹ · Vincent Chow¹ · Zhiying Pan¹ · Vladimir Hanes¹

Published online: 20 November 2017
© The Author(s) 2017. This article is an open access publication

**Correction to: Cancer Chemother Pharmacol
(2017) 80:755–763
<https://doi.org/10.1007/s00280-017-3416-4>**

The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men], written by [Richard Markus, Vincent Chow, Zhiying Pan and Vladimir Hanes], was originally published Online First without open access. After publication in volume [80], issue [4], page [755–763] the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) [2017] and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/by/4.0/)

[by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The original article was corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The online version of the original article can be found under
<https://doi.org/10.1007/s00280-017-3416-4>.

✉ Vladimir Hanes
vhanes@amgen.com

¹ Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA